Thomas J Little

US Patent:

20130196994, Aug 1, 2013

Filed:

Nov 16, 2012

Appl. No.:

13/679818

Inventors:

Omeros Corporation - Seattle WA, US
Jennifer Lynn Gage - Kenmore WA, US
Thomas Neil Wheeler - Raleigh NC, US
Thomas L. Little - Redmond WA, US

Assignee:

OMEROS CORPORATION - Seattle WA

International Classification:

A61K 31/5377
A61K 31/422
A61K 31/454
A61K 31/421
A61K 31/4709
A61K 31/4245
A61K 31/497
A61K 31/433
A61K 31/4155
A61K 31/341
A61K 31/4545
A61K 31/4192
A61K 31/4196
A61K 31/415
A61K 31/427

US Classification:

5142362, 5142368, 514365, 5142358, 514374, 514326, 514314, 514364, 51425505, 5142365, 5142315, 514363, 514406, 514461, 514372, 514333, 514359, 514383, 5142355

Abstract:

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

US Patent:

20200276190, Sep 3, 2020

Filed:

Nov 13, 2019

Appl. No.:

16/682665

Inventors:

- Seattle WA, US
Neil S. Cutshall - Cutshall WA, US
Gregory A. Demopulos - Mercer Island WA, US
George A. Gaitanaris - Seattle WA, US
Alexander Gragerov - Seattle WA, US
Thomas L. Little - Seattle WA, US
Rene Onrust - Mercer Island WA, US

International Classification:

A61K 31/496
A61K 31/473
A61K 31/495
A61K 31/381
A61K 31/502
A61K 31/55

Abstract:

GPR174 is an orphan receptor that has been implicated in cancer, nervous system diseases and disorders and neuroregeneration. We have identified inhibitors of GPR174 and have identified the G-protein signaling pathways that GPR174 modulates. Based on this discovery, the present invention features methods for inhibiting GPR174 activity and thereby stimulating an immune response in a subject in need thereof, particularly in the use of treatment of non-malignant neoplasms, malignant neoplasms (i.e., cancer), nervous system diseases and disorders and neuroregeneration, as well as related compositions.